Epidemiology, Clinical Manifestations, Treatment, and Outcome of Mucormycosis: A Review of 77 Cases From a Single Center in France.

diagnosis epidemiology immunosuppressed mucormycosis outcome

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 10 04 2024
accepted: 16 07 2024
medline: 26 8 2024
pubmed: 26 8 2024
entrez: 26 8 2024
Statut: epublish

Résumé

The aim of this study was to assess the epidemiology, clinical manifestations, and outcome of mucormycosis over 15 years in a single center in France. We conducted a retrospective analysis of all mucormycosis cases in our institution from 1 January 2006 to 31 December 2020 and analyzed patients' medical records, laboratory results, and treatment to describe the epidemiology, clinical manifestations, diagnosis, treatment, and outcome. Mucorales quantitative polymerase chain reaction (qPCR) for the diagnosis was implemented in 2015. Seventy-seven mucormycosis cases were analyzed in 77 patients, with a median age of 54 years (60% male). Identified risk factors were hematological diseases (46 cases [60%]), solid malignancies (2 cases), solid organ transplants (3), burns (18), diabetes only (7), and trauma (1). Sites of infection were lungs (42%), sinus (36%), skin (31%), central nervous system (9%), liver (8%), others (6%), and disseminated (12%). Diagnosis remained difficult and qPCR contributed to mucormycosis diagnosis in 30% of cases. Among hematology patients, serum qPCR was the only positive test in 15% of cases. A mixed mold infection was diagnosed in 24 of 77 (31%) patients. Surgical treatment was undertaken in 43 (56%) cases. Most patients received liposomal amphotericin B (89%), with a combination therapy in 18 of 77 cases (23%). Three-month survival rate was 40% (95% confidence interval [CI], .30-.53]). As for treatment, adjunction of surgery (hazard ratio, 0.47 [95%CI, .25-.91); Mucormycosis remained associated with high mortality, especially in the hematological and burn populations. Surgery in combination with antifungal treatment was associated with improved survival.

Sections du résumé

Background UNASSIGNED
The aim of this study was to assess the epidemiology, clinical manifestations, and outcome of mucormycosis over 15 years in a single center in France.
Methods UNASSIGNED
We conducted a retrospective analysis of all mucormycosis cases in our institution from 1 January 2006 to 31 December 2020 and analyzed patients' medical records, laboratory results, and treatment to describe the epidemiology, clinical manifestations, diagnosis, treatment, and outcome. Mucorales quantitative polymerase chain reaction (qPCR) for the diagnosis was implemented in 2015.
Results UNASSIGNED
Seventy-seven mucormycosis cases were analyzed in 77 patients, with a median age of 54 years (60% male). Identified risk factors were hematological diseases (46 cases [60%]), solid malignancies (2 cases), solid organ transplants (3), burns (18), diabetes only (7), and trauma (1). Sites of infection were lungs (42%), sinus (36%), skin (31%), central nervous system (9%), liver (8%), others (6%), and disseminated (12%). Diagnosis remained difficult and qPCR contributed to mucormycosis diagnosis in 30% of cases. Among hematology patients, serum qPCR was the only positive test in 15% of cases. A mixed mold infection was diagnosed in 24 of 77 (31%) patients. Surgical treatment was undertaken in 43 (56%) cases. Most patients received liposomal amphotericin B (89%), with a combination therapy in 18 of 77 cases (23%). Three-month survival rate was 40% (95% confidence interval [CI], .30-.53]). As for treatment, adjunction of surgery (hazard ratio, 0.47 [95%CI, .25-.91);
Conclusions UNASSIGNED
Mucormycosis remained associated with high mortality, especially in the hematological and burn populations. Surgery in combination with antifungal treatment was associated with improved survival.

Identifiants

pubmed: 39183813
doi: 10.1093/ofid/ofae426
pii: ofae426
pmc: PMC11342388
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofae426

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. All authors: No reported conflicts.

Auteurs

Blandine Denis (B)

Department of Infectious Diseases, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.

Matthieu Resche-Rigon (M)

Department of Biomedical Statistics and Methodology, Hôpital Saint-Louis, Fernand Widal, Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Université Paris Cité, Paris, France.

Emmanuel Raffoux (E)

Université Paris Cité, Paris, France.
Department of Hematology, Hôpital Saint-Louis, Fernand Widal, Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France.

Anne-Marie Ronchetti (AM)

Department of Hematology, Hôpital Saint-Louis, Fernand Widal, Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France.

Emmanuel Dudoignon (E)

Université Paris Cité, Paris, France.
Department of Burn Intensive Care Unit, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.

Benjamin Verillaud (B)

Department of Head and Neck surgery, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Inserm U1131, Université Paris Cité, Paris, France.

Sandrine Valade (S)

Department of Intensive Care Medicine, Hôpital Saint-Louis, Fernand Widal, Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France.

Gwenaël Lorillon (G)

Department of Pneumology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.

Florence Rabian (F)

Department of Hematology-Teenagers and Young Adults Unit, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.

Aliénor Xhaard (A)

Service d'hematologie-greffes, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.

Sophie Touratier (S)

Department of Pharmacy, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.

Samia Hamane (S)

Laboratoire de parasitologie-mycologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.

Alexandre Alanio (A)

Laboratoire de parasitologie-mycologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
Département de mycologie, Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, Groupe de recherche Mycologie Translationnelle Paris, France.

Nathalie De Castro (N)

Department of Infectious Diseases, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
Université Paris Cité, Paris, France.

Classifications MeSH